As you will see just below, this post falls under the category of a thinly veiled and somewhat shameless plug which I hope you'll tolerate if I'm transparent about it upfront and I add what may be a little useful commentary along the way.
I won't have to convince "regular" readers of this "irregular" blog that regenerative medicine is one of the fastest growing life science sectors.
Given the pace of the industry's growth, the amount of public money being "invested" in the sector, and the general enthusiasm that the science generates, it is no surprise that is increasingly an area of interest for those seeking a new career path.
One commonly held misconception is that career opportunities in the sector are limited largely to those in early-stage research.
While it is true that the industry is still in the nascent stages of commercial development compared to other more mature segments in the broader biopharmaceutical industry, careers in regenerative medicine span the full research and commercial spectrum from pre-clinical to clinical research in both academic and corporate settings, manufacturing, regulatory, quality, operations, logistics, finance, business development, marketing, sales, communications, and executive management.
As has been discussed here in the past, most analysts agree that in 2008 the industry passed the $1 billion mark in annual revenue generated from sale of approved therapeutic products falling under the regenerative medicine category (see here for more in-depth analysis).
Furthermore, most large multinational life science companies are now investing heavily into the sector on the promise that it will revolutionize healthcare in the coming decades.
I believe the 2008 decision by Pfizer to create a substantial new Regenerative Medicine division will be seen as a seminal turning point in corporate perspectives on the industry. Since that point most life sciences have begun investing in regenerative medicine strategies and the trend has even leaked outside of life science to companies such as Google Ventures which has informally identified regenerative medicine as one of their primary areas of interest when looking at companies in which to invest.
Most major universities have now created both academic and research programs dedicated to the emerging field of regenerative medicine such that there is a new class of graduates now emerging in both scientific and commercial disciplines with regenerative medicine as a primary focus.
However, one of the difficulties with finding a career in regenerative medicine is that it is comprised of what has heretofore been fairly discrete disciplines of stem cell biology, pharmaceutical sciences, biotechnology, tissue engineering, stem cell transplantation, device technologies, cell therapies, etc.
Furthermore, most recruiters and online job sites have very little experience or focus on the industry making recruiting difficult for positions in regenerative medicine companies or departments. The task is further complicated by the fact that the candidate pool is small and diversely spread over a multitude of disciplines, centers, and a multitude of small companies.
Finally there are only now emerging industry publications, organizations, online communities, and websites that truly represent the broad spectrum of regenerative medicine and that can be used as central resources for recruiting.
All this is why my partners and I saw the need for an online recruiting tool that really focused on regenerative medicine in a way that would support the industry's maturation. What we wanted to bring was a very simple solution that would create as much value as possible for those looking to recruit the right talent into their regenerative medicine efforts. This was the genesis behind RegenerativeMedicineJobs.com.
(here comes the shameless part....)
About RMJ
At RegenerativeMedicineJobs.com, we believe the growth trajectory of this industry requires a specialized, online recruiting system – one that is more than just a website for posting jobs but also plugged into the large and diverse network of associations, publications, and social media that serves this industry.
RegenerativeMedicineJobs.com is a specialized online job board focused on recruiting for positions in the rapidly growing field of regenerative medicine. The site is simple to use and focused in scope. But this is more than just another website.
RMJ has developed a sophisticated system designed to leverage our extensive network in RM to ensure every post gets maximum attention and attracts the best candidates.
Traffic is pulled to the site and job postings are pushed to a targeted audience by focused social media and marketing campaigns. This is the latest way to recruit for any position in a regenerative medicine department, division, or company. This is regenerative medicine recruiting with a focus.
RegenerativeMedicineJobs.com (RMJ) is a collaboration between CTG Consulting, Co. and Pencilneck Software, Co. The personnel behind this collaboration created Cell Therapy News, Cell Therapy Blog, the LinkedIn Cell Therapy Industry Group, and have produced over a dozen organizational or event-based websites in the cell therapy, stem cell, and regenerative medicine space.
The site has been designed to be simple and intuitive with only one goal in mind: to be the best online tool for recruiting personnel into positions in the regenerative medicine industry.
We don't offer resume posting, career advice, assistance building your CV, hand holding, shoulders to cry on, or job postings outside of regenmed. We believe in the value of specialization.
The site is a listing of regenerative medicine jobs (period). All types of jobs for all types of organizations but only regenmed job (period).
We have only one rule: the jobs posted must be for a position within the regenerative medicine space. We define regenerative medicine as anything involving cell therapy, stem cells as therapies or tools for discovery or toxicity testing, or non-cell based programs/products (e.g., small molecules, biologics, devices, etc) used to replace or regenerate cells, tissues, or organs to restore, repair, or establish normal function.
The site has a topical niche with no regional focus or bias. This is meant to be a global tool equally useful for a company or university in Poland, Taiwan, Brazil, the United States, etc.
The site is also meant to be useful for recruiting any positions scientific or commercial, business or technical, executive or laborer.
*
We hope you find it useful.
We hope it contributes to the industry's growth and maturation.
We hope you will provide us feedback on what we're doing well and what we can do better.
- Stem cells for a Webby! [Last Updated On: August 18th, 2024] [Originally Added On: April 28th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: August 18th, 2024] [Originally Added On: April 30th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: August 18th, 2024] [Originally Added On: April 30th, 2010]
- Google to Invest in Regenerative Medicine [Last Updated On: August 18th, 2024] [Originally Added On: May 5th, 2010]
- Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: August 18th, 2024] [Originally Added On: May 22nd, 2010]
- The changing face of PR and why it matters to regenmed [Last Updated On: August 18th, 2024] [Originally Added On: June 12th, 2010]
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 18th, 2024] [Originally Added On: August 12th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: August 18th, 2024] [Originally Added On: October 11th, 2010]
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: August 18th, 2024] [Originally Added On: February 14th, 2011]
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: August 18th, 2024] [Originally Added On: February 14th, 2011]
- In vivo cell trafficking just took a leap forward [Last Updated On: August 18th, 2024] [Originally Added On: July 3rd, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: August 18th, 2024] [Originally Added On: July 10th, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: August 18th, 2024] [Originally Added On: July 10th, 2011]
- Clinical trial costs [Last Updated On: August 18th, 2024] [Originally Added On: July 31st, 2011]
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 18th, 2024] [Originally Added On: August 14th, 2011]
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: August 18th, 2024] [Originally Added On: September 18th, 2011]
- Commercial-stage Cell Therapy Companies and Products [Last Updated On: August 18th, 2024] [Originally Added On: September 18th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: August 18th, 2024] [Originally Added On: September 25th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: August 18th, 2024] [Originally Added On: September 25th, 2011]
- Commercializing Cell-based Regenerative Medicines [Last Updated On: August 18th, 2024] [Originally Added On: November 13th, 2011]
- Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: August 18th, 2024] [Originally Added On: November 27th, 2011]
- Active phase III or II/III cell therapy trials [Last Updated On: August 18th, 2024] [Originally Added On: December 11th, 2011]
- Recently approved cell therapy products [Last Updated On: August 18th, 2024] [Originally Added On: December 18th, 2011]
- Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: August 18th, 2024] [Originally Added On: December 18th, 2011]
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: August 18th, 2024] [Originally Added On: January 1st, 2012]
- Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? [Last Updated On: August 18th, 2024] [Originally Added On: March 11th, 2012]
- Another > $100M month for companies in the cell therapy space [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2012]
- Another > $100M month for companies in the cell therapy space [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2012]
- Cell-based Cancer Immunotherapies. Some metrics.. [Last Updated On: August 18th, 2024] [Originally Added On: May 20th, 2012]
- Industry-sponsored cardiovascular cell therapies. Some metrics. [Last Updated On: August 18th, 2024] [Originally Added On: May 27th, 2012]
- Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing [Last Updated On: August 18th, 2024] [Originally Added On: June 17th, 2012]
- FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) [Last Updated On: August 18th, 2024] [Originally Added On: July 29th, 2012]
- Is the cell therapy sector outperforming the major indices? [Last Updated On: August 18th, 2024] [Originally Added On: August 12th, 2012]
- Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: August 18th, 2024] [Originally Added On: September 2nd, 2012]
- Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: August 18th, 2024] [Originally Added On: September 2nd, 2012]
- Two lessons I learned this week. [Last Updated On: August 18th, 2024] [Originally Added On: September 16th, 2012]
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- Anticipated short-term cell therapy industry clinical milestones [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- Cell therapy portfolio outperforms major indices year-to-date [Last Updated On: August 18th, 2024] [Originally Added On: October 14th, 2012]
- CIRM addresses some tough questions. Is it all just glass towers and basic research? [Last Updated On: August 18th, 2024] [Originally Added On: October 21st, 2012]
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: August 18th, 2024] [Originally Added On: November 4th, 2012]
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: August 18th, 2024] [Originally Added On: November 4th, 2012]
- Cell Therapy Industry Group Welcomes its 4,000th member [Last Updated On: August 18th, 2024] [Originally Added On: November 11th, 2012]
- Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. [Last Updated On: August 18th, 2024] [Originally Added On: December 2nd, 2012]
- A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments [Last Updated On: August 18th, 2024] [Originally Added On: December 16th, 2012]
- The ROI on pant-wearing and other social media tips [Last Updated On: August 18th, 2024] [Originally Added On: December 16th, 2012]
- The Accuracy of Adipose Stem Cell Doses [Last Updated On: August 18th, 2024] [Originally Added On: December 23rd, 2012]
- Cell Therapy Blog welcomes 2013 [Last Updated On: August 18th, 2024] [Originally Added On: January 6th, 2013]
- 2013 Annual Regenerative Medicine Industry Report [Last Updated On: August 18th, 2024] [Originally Added On: April 21st, 2013]
- Commercialization of Regenerative Medicine: Learning from Spin-Outs [Last Updated On: August 18th, 2024] [Originally Added On: April 28th, 2013]